Aristotle University Of Thessaloniki (AUTH)
Μελέτη της προστατευτικής δράσης της αντιθρομβίνης ΙΙΙ στην καρδιά και στους πνεύμονες στο σύνδρομο οξείας ισχαιμίας - επαναιμάτωσης των οπισθίων άκρων: πειραματική μελέτη σε επίμυες
Abstract
dc:descriptionIntroduction: Acute ischemia-reperfusion of a lower limb could cause injury to distal organs (remote ischemia-reperfusion) and systematic inflammation response resulting in high mortality rates. Lipid hyperoxidation, caused by oxygen-free radicals released in the systematic circulation after the reperfusion, has been predicted as the major factor of the systematic response. Tissue levels of Malondialdehyde (MDA), which is one of the end products of the lipid hyperoxidation, has been used to measure indirectly the levels of oxygen-free radicals. Antithrombin III (AT III) is a single-chain glycoprotein which is produced by the liver and besides its coagulation role has also been shown to have marked anti-inflammatory effects and a half-life of 2-3 days. Purpose: The study of AT III as a protective factor against lung and myocardial injury after acute ischemia and reperfusion of the lower limb. Materials and Methods: 80 Wistar rats, weighing 250-300 gr, had been studied. Ischemia was produced by the application of a 0' Prolene suture ligature on the right hind limb. Ischemia was confirmed by Doppler and, in some cases, by arteriography. Animals were divided into those receiving AT III (dose 250mg/kg, Kybernin P; Aventis Behring GmbH) 30 minutes before the reperfusion (group A, n=30), and those receiving placebo (group B, n=30). Animals were then sacrificed. Blood samples for white blood cell (WBC) count, platelets (PLT), SGOT, SGPT, ALP and γ-GT taken from the vena cava and lung and myocardial tissue samples were taken at baseline, 30 minutes, and 4 hours after reperfusion for tissue MDA levels and light microscopy. Results: Increased WBC levels had been found in both groups after reperfusion, but no significant changes had been observed between the two groups. In the AT III group, SGOT levels were significant lower at 4 hours after reperfusion. No noticeable changes had been found between the two groups with regard to the biochemistry parameters tested (SGPT, ALP, γ-GT). In the lung tissue, MDA levels were significantly lower in the AT III group compared to the placebo group at baseline (p=0.001) and at 30 minutes (p=0.02) post reperfusion, but not at 4 hours (p=0.9). In total, MDA levels were found significantly reduced in the AT III group compared to placebo (p=0.005). In addition, significantly decreased MDA levels had been identified in the AT III group at baseline (zero time) post-reperfusion when compared to a sham group, i.e. those animals receiving AT III without ischemia-reperfusion (p=0.002).Optical microscopy of the tissue samples did not identify any significant differences between the two groups. Light microscopy examination with electron microscope revealed decreased damage in cell level for the AT III group. In the cardiac tissue, the AT III group, as a total, was found to have significantly lower MDA levels compared with the placebo group (p= 0.005). However, no statistically significant differences existed between the two groups at zero reperfusion time (p=0.07), 30 minutes (p=0.07) and 4 hours (p=0.2). Using light microscopy, sarcomeria disruption, intercellular oedema and free microfibers had all been found at 4 hours after reperfusion in the placebo group, but not in the AT III group. In addition, the intracellular oedema, which was found in the placebo group at baseline, was not noted in the AT III group. Optical microscopy did not reveal any noticeable changes between the two groups. Conclusions: Pretreatment with AT III 30 minutes before the reperfusion of an acutely ischemic limb can reduce the oxidant stress to lung and, less so, to myocardial tissue due to its anti-inflammatory and antioxidant action.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2010
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Zambas, Neofytos
- Ζαμπάς, Νεόφυτος
Subjects
dc:subject × 14Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/28324